Clinical Trials Logo

Filter by:
NCT ID: NCT03875001 Completed - Healthy Clinical Trials

A Study About How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated in Healthy Japanese Men

Start date: March 25, 2019
Phase: Phase 1
Study type: Interventional

The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1358894 in healthy male subjects following oral administration of single rising doses.

NCT ID: NCT03874013 Completed - Clinical trials for Growth Hormone Deficiency

Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency

Start date: December 7, 2017
Phase: Phase 3
Study type: Interventional

Treatment of children with growth failure due to growth hormone deficiency (GHD). Primary • To evaluate the efficacy and safety of weekly MOD-4023 administration compared to daily Genotropin® administration in Japanese pre-pubertal children with GHD. Secondary • To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) profiles of three different doses of MOD-4023 in Japanese pre-pubertal children with GHD.

NCT ID: NCT03873116 Completed - Clinical trials for Hereditary Angioedema, HAE

Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan

APeX-J
Start date: February 28, 2019
Phase: Phase 3
Study type: Interventional

This is a phase 3, multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of oral BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE who live in Japan.

NCT ID: NCT03870087 Completed - Clinical trials for Coronary Artery Disease

PRECISION GRX Post-Market Study - Japan

Start date: April 12, 2019
Phase:
Study type: Observational [Patient Registry]

To collect data on the routine patterns of use, safety and effectiveness, including the clinical and technical performance of the CorPath GRX System, in the delivery and manipulation of coronary guidewires and stent/balloon catheters, and manipulation of guide catheters during PCI procedures in the first 231 patients treated with the CorPath device in Japan.

NCT ID: NCT03864458 Completed - Hyperphosphatemia Clinical Trials

Dose-finding Study of KHK7791 in Hyperphosphatemia Patients

Start date: April 15, 2019
Phase: Phase 2
Study type: Interventional

To evaluate the effect and safety of KHK7791 to treat Hyperphosphatemia in ptatients on HD.

NCT ID: NCT03864445 Completed - Hyperphosphatemia Clinical Trials

Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients

Start date: April 29, 2019
Phase: Phase 2
Study type: Interventional

To evaluate the effect and safety of KHK7791 in combination with phosphate binders to treat Hyperphosphatemia in ptatients on HD.

NCT ID: NCT03864185 Completed - Clinical trials for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies

RECIPE
Start date: March 28, 2019
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of rituximab (genetical recombination) intravenously administered to CIDP patients with positive or negative IgG4 autoantibody.

NCT ID: NCT03861052 Completed - Type 2 Diabetes Clinical Trials

A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes

SURPASS J-mono
Start date: May 7, 2019
Phase: Phase 3
Study type: Interventional

The reason for this study is to see if the study drug tirzepatide (LY3298176) is effective and safe compared to dulaglutide in participants with type 2 diabetes in Japan.

NCT ID: NCT03861039 Completed - Clinical trials for Type 2 Diabetes Mellitus

A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

Start date: March 30, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the long-term safety of the study drug tirzepatide in combination with oral antihyperglycemic medications in participants with type 2 diabetes.

NCT ID: NCT03859427 Completed - Clinical trials for Relapsed or Refractory Multiple Myeloma

A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

ARROW2
Start date: May 8, 2019
Phase: Phase 3
Study type: Interventional

Compare efficacy of 56 mg/m2 carfilzomib administered once-weekly in combination with lenalidomide and dexamethasone (KRd 56 mg/m2) to 27 mg/m2 carfilzomib administered twice-weekly in combination with lenalidomide and dexamethasone (KRd 27 mg/m2) in subjects with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy.